nach oben

European Archives of Psychiatry and Clinical Neuroscience

Erschienen in:

29.05.2018 | Original Paper

Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimer’s disease patients

verfasst von: Jessyka Maria de França Bram, Leda Leme Talib, Helena Passarelli Giroud Joaquim, Tamires Alves Sarno, Wagner Farid Gattaz, Orestes Vicente Forlenza

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

The clinical diagnosis of Alzheimer’s disease (AD) is a probabilistic formulation that may lack accuracy particularly at early stages of the dementing process. Abnormalities in amyloid-beta precursor protein (APP) metabolism and in the level of APP secretases have been demonstrated in platelets, and to a lesser extent in leukocytes, of AD patients, with conflicting results. The aim of the present study was to compare the protein level of the APP secretases A-disintegrin and metalloprotease 10 (ADAM10), Beta-site APP-cleaving enzyme 1 (BACE1), and presenilin-1 (PSEN1) in platelets and leukocytes from 20 non-medicated older adults with AD and 20 healthy elders, and to determine the potential use of these biomarkers to discriminate cases of AD from controls. The protein levels of all APP secretases were significantly higher in platelets compared to leukocytes. We found statistically a significant decrease in ADAM10 (52.5%, p < 0.0001) and PSEN1 (32%, p = 0.02) in platelets from AD patients compared to controls, but not in leukocytes. Combining all three secretases to generate receiver-operating characteristic (ROC) curves, we found a good discriminatory effect (AD vs. controls) when using platelets (the area under the curve—AUC—0.90, sensitivity 88.9%, specificity 66.7%, p = 0.003), but not in leukocytes (AUC 0.65, sensitivity 77.8%, specificity 50.0%, p = 0.2). Our findings indicate that platelets represent a better biological matrix than leukocytes to address the peripheral level of APP secretases. In addition, combining the protein level of ADAM10, BACE1, and PSEN1 in platelets, yielded a good accuracy to discriminate AD from controls.

Barthel H, Gertz H-J, Dresel S et al (2011) Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 10:424–435. https://doi.org/10.1016/S1474-4422(11)70077-1 CrossRefPubMed

McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement 7:263–269. https://doi.org/10.1016/j.jalz.2011.03.005 CrossRef

Henriksen K, O’Bryant SE, Hampel H et al (2014) The future of blood-based biomarkers for Alzheimer’s disease. Alzheimer’s Dement 10:115–131. https://doi.org/10.1016/j.jalz.2013.01.013 CrossRef

O’Bryant SE (2016) Introduction to special issue on Advances in blood-based biomarkers of Alzheimer’s disease. Alzheimer’s Dement (Amst Neth) 3:110–112. https://doi.org/10.1016/j.dadm.2016.06.003 CrossRef

O’Bryant SE, Mielke MM, Rissman RA et al (2017) Blood-based biomarkers in Alzheimer disease: current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimer’s Dement 13:45–58. https://doi.org/10.1016/j.jalz.2016.09.014 CrossRef

Bussière T, Giannakopoulos P, Bouras C et al (2003) Progressive degeneration of nonphosphorylated neurofilament protein-enriched pyramidal neurons predicts cognitive impairment in Alzheimer’s disease: stereologic analysis of prefrontal cortex area 9. J Comp Neurol 463:281–302. https://doi.org/10.1002/cne.10760 CrossRefPubMed

Rodgers A (2008) Alzheimer’s disease: unraveling the mystery. Alzheimer’s Disease Education and Referral (ADEAR) Center, Silver Spring

Qin W, Ho L, Wang J et al (2009) S100A7, a novel Alzheimer’s disease biomarker with non-amyloidogenic α-secretase activity acts via selective promotion of ADAM-10. PLoS One 4:e4183. https://doi.org/10.1371/journal.pone.0004183 CrossRefPubMedPubMedCentral

Yoon S-S, Jo SA (2012) Mechanisms of amyloid-β peptide clearance: potential therapeutic targets for Alzheimer’s disease. Biomol Ther (Seoul) 20:245–255. https://doi.org/10.4062/biomolther.2012.20.3.245 CrossRef

10.

Jack CR, Knopman DS, Jagust WJ et al (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 9:119–128. https://doi.org/10.1016/S1474-4422(09)70299-6 CrossRefPubMedPubMedCentral

11.

Blennow K, Dubois B, Fagan AM et al (2015) Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease. Alzheimer’s Dement 11:58–69. https://doi.org/10.1016/j.jalz.2014.02.004 CrossRef

12.

Blennow K (2017) A review of fluid biomarkers for Alzheimer’s disease: moving from CSF to blood. Neurol Ther 6:15–24. https://doi.org/10.1007/s40120-017-0073-9 CrossRefPubMedPubMedCentral

13.

Galasko D, Golde TE (2013) Biomarkers for Alzheimer’s disease in plasma, serum and blood—conceptual and practical problems. Alzheimers Res Ther 5:10. https://doi.org/10.1186/alzrt164 CrossRefPubMedPubMedCentral

14.

Gisslén M, Price RW, Andreasson U et al (2016) Plasma Concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine 3:135–140. https://doi.org/10.1016/j.ebiom.2015.11.036 CrossRefPubMed

15.

Bayer T, Cappai R, Masters C et al (1999) It all sticks together—the APP-related family of proteins and Alzheimer’s disease. Mol Psychiatry 4:524–528. https://doi.org/10.1038/sj.mp.4000552 CrossRefPubMed

16.

Di Luca M, Colciaghi F, Pastorino L et al (2000) Platelets as a peripheral district where to study pathogenetic mechanisms of Alzheimer disease: the case of amyloid precursor protein. Eur J Pharmacol 405:277–283CrossRefPubMed

17.

Skovronsky DM, Lee VM-Y, Praticò D (2001) Amyloid precursor protein and amyloid β peptide in human platelets. J Biol Chem 276:17036–17043. https://doi.org/10.1074/jbc.M006285200 CrossRefPubMed

18.

Racchi M, Govoni S (2003) The pharmacology of amyloid precursor protein processing. Exp Gerontol 38:145–157CrossRefPubMed

19.

Haass C (2004) Take five–BACE and the gamma-secretase quartet conduct Alzheimer’s amyloid beta-peptide generation. EMBO J 23:483–488. https://doi.org/10.1038/sj.emboj.7600061 CrossRefPubMedPubMedCentral

20.

Zainaghi IA, Forlenza OV, Gattaz WF (2007) Abnormal APP processing in platelets of patients with Alzheimer’s disease: correlations with membrane fluidity and cognitive decline. Psychopharmacology 192:547–553. https://doi.org/10.1007/s00213-007-0748-5 CrossRefPubMed

21.

Cole SL, Vassar R (2008) BACE1 structure and function in health and Alzheimer’s disease. Curr Alzheimer Res 5:100–120. https://doi.org/10.2174/156720508783954758 CrossRefPubMed

22.

Seals DF, Courtneidge SA (2003) The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 17:7–30. https://doi.org/10.1101/gad.1039703 CrossRefPubMed

23.

Chang C, Werb Z (2001) The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 11:S37-43CrossRefPubMed

24.

Vingtdeux V, Marambaud P (2012) Identification and biology of α-secretase. J Neurochem 120:34–45. https://doi.org/10.1111/j.1471-4159.2011.07477.x CrossRefPubMed

25.

Schellenberg G, Bird T, Wijsman E et al (1992) Genetic linkage evidence for a familial Alzheimer’s disease locus on chromosome 14. Science 258:668–671. https://doi.org/10.1126/science.1411576 CrossRefPubMed

26.

De Strooper B (2003) Aph-1, Pen-2, and nicastrin with Presenilin generate an active γ-secretase complex. Neuron 38:9–12CrossRefPubMed

27.

Tang K, Hynan LS, Baskin F, Rosenberg RN (2006) Platelet amyloid precursor protein processing: a bio-marker for Alzheimer’s disease. J Neurol Sci 240:53–58. https://doi.org/10.1016/j.jns.2005.09.002 CrossRefPubMed

28.

Zainaghi IA, Talib LL, Diniz BS et al (2012) Reduced platelet amyloid precursor protein ratio (APP ratio) predicts conversion from mild cognitive impairment to Alzheimer’s disease. J Neural Transm 119:815–819. https://doi.org/10.1007/s00702-012-0807-x CrossRefPubMed

29.

Diniz BSO, Pinto JA, Forlenza OV (2008) Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer’s disease? A systematic review and meta-analysis of the literature. World J Biol Psychiatry 9:172–182. https://doi.org/10.1080/15622970701535502 CrossRefPubMed

30.

Forlenza OV, Diniz BS, Teixeira AL et al (2015) Lower cerebrospinal fluid concentration of brain-derived neurotrophic factor predicts progression from mild cognitive impairment to Alzheimer’s disease. NeuroMol Med 17:326–332. https://doi.org/10.1007/s12017-015-8361-y CrossRef

31.

Forlenza OV, Radanovic M, Talib LL et al (2015) Cerebrospinal fluid biomarkers in Alzheimer’s disease: diagnostic accuracy and prediction of dementia. Alzheimer’s dement diagnosis. Assess Dis Monit 1:455–463. https://doi.org/10.1016/j.dadm.2015.09.003 CrossRef

32.

Gardella JE, Gorgone GA, Newman P et al (1992) Characterization of Alzheimer amyloid precursor protein transcripts in platelets and megakarocytes. Neurosci Lett 138:229–232. https://doi.org/10.1016/0304-3940(92)90921-S CrossRefPubMed

33.

Veitinger M, Varga B, Guterres SB, Zellner M (2014) Platelets, a reliable source for peripheral Alzheimer’s disease biomarkers? Acta Neuropathol Commun 2:65. https://doi.org/10.1186/2051-5960-2-65 CrossRefPubMedPubMedCentral

34.

Rosenberg RN, Baskin F, Fosmire JA et al (1997) Altered amyloid protein processing in platelets of patients with Alzheimer disease. Arch Neurol 54:139–144CrossRefPubMed

35.

Bush AI, Tanzi RE (1998) Alzheimer-disease-related abnormalities of amyloid β precursor protein isoforms in the platelet—the brains delegate in the periphery. Arch Neurol 55:1179–1180. https://doi.org/10.1001/archneur.55.9.1179 CrossRefPubMed

36.

Di Luca M (1998) Differential level of platelet amyloid beta precursor protein isoforms: an early marker for Alzheimer disease. Arch Neurol 55:1195–1200. https://doi.org/10.1001/archneur.55.9.1195 CrossRefPubMed

37.

Li Q, Whyte S, Tanner J et al (1998) Secretion of Alzheimer’s disease Abeta amyloid peptide by activated human platelets. Lab Investig 78:461–469PubMed

38.

Li QX, Evin G, Small DH et al (1995) Proteolytic processing of Alzheimer’s disease ?βA4 amyloid precursor protein in human platelets. J Biol Chem 270:14140–14147. https://doi.org/10.1074/jbc.270.23.14140 CrossRefPubMed

39.

Evin G, Zhu A, Holsinger RMD et al (2003) Proteolytic processing of the Alzheimer’s disease amyloid precursor protein in brain and platelets. J Neurosci Res 74:386–392. https://doi.org/10.1002/jnr.10745 CrossRefPubMed

40.

Golde TE, Estus S, Usiak M et al (1990) Expression of beta amyloid protein precursor mRNAs: recognition of a novel alternatively spliced form and quantitation in alzheimer’s disease using PCR. Neuron 4:253–267. https://doi.org/10.1016/0896-6273(90)90100-T CrossRefPubMed

41.

Mönning U, König G, Banati RB et al (1992) Alzheimer beta A4-amyloid protein precursor in immunocompetent cells. J Biol Chem 267:23950–23956PubMed

42.

Li QX, Berndt MC, Bush AI et al (1994) Membrane-associated forms of the beta A4 amyloid protein precursor of Alzheimer’s disease in human platelet and brain: surface expression on the activated human platelet. Blood 84:133–142CrossRefPubMed

43.

Delvaux E, Bentley K, Stubbs V et al (2013) Differential processing of amyloid precursor protein in brain and in peripheral blood leukocytes. Neurobiol Aging 34:1680–1686. https://doi.org/10.1016/j.neurobiolaging.2012.12.004 CrossRefPubMedPubMedCentral

44.

Schuck F, Wolf D, Fellgiebel A, Endres K (2016) Increase of α-secretase ADAM10 in platelets along cognitively healthy aging. J Alzheimer’s Dis 50:817–826. https://doi.org/10.3233/JAD-150737 CrossRef

45.

Vidal R, Ghiso J, Wisniewski T, Frangione B (1996) Alzheimer’s presenilin 1 gene expression in platelets and megakaryocytes. FEBS Lett 393:19–23. https://doi.org/10.1016/0014-5793(96)00845-9 CrossRefPubMed

46.

Colciaghi F, Borroni B, Pastorino L et al (2002) [alpha]-Secretase ADAM10 as well as [alpha]APPs is reduced in platelets and CSF of Alzheimer disease patients. Mol Med 8:67–74CrossRefPubMedPubMedCentral

47.

Decourt B, Walker A, Gonzales A et al (2013) Can platelet BACE1 levels be used as a biomarker for Alzheimer’s disease? Proof-of-concept study. Platelets 24:235–238. https://doi.org/10.3109/09537104.2012.688899 CrossRefPubMed

48.

Manzine PR, de França Bram JM, Barham EJ et al (2013) ADAM10 as a biomarker for Alzheimer’s disease: a Study with Brazilian Elderly. Dement Geriatr Cogn Disord 35:58–66. https://doi.org/10.1159/000345983 CrossRefPubMed

49.

Marksteiner J, Humpel C (2013) Platelet-derived secreted amyloid-precursor protein-β as a marker for diagnosing Alzheimer’s disease. Curr Neurovasc Res 10:297–303CrossRefPubMedPubMedCentral

50.

Sarno TA, Talib LL, Joaquim HPG et al (2017) Protein expression of BACE1 is downregulated by Donepezil in Alzheimer’s disease platelets. J Alzheimers Dis 55:1445–1451. https://doi.org/10.3233/JAD-160813 CrossRefPubMed

51.

Rogaev EI, Sherrington R, Wu C et al (1997) Analysis of the 5? Sequence, genomic structure, and alternative splicing of thepresenilin-1gene (psen1) associated with early onset Alzheimer disease. Genomics 40:415–424. https://doi.org/10.1006/geno.1996.4523 CrossRefPubMed

52.

Decourt B, Sabbagh MN (2011) BACE1 as a potential biomarker for Alzheimer’s disease. J Alzheimers Dis 24(Suppl 2):53–59. https://doi.org/10.3233/JAD-2011-110017 CrossRefPubMedPubMedCentral

53.

Delvaux E, Bentley K, Stubbs V et al Differential processing of amyloid precursor protein in brain and in peripheral blood leukocytes. https://doi.org/10.1016/j.neurobiolaging.2012.12.004 CrossRefPubMedPubMedCentral

54.

American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DC

55.

McKhann G, Drachman D, Folstein M et al (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–939. https://doi.org/10.1212/WNL.34.7.939 CrossRefPubMed

56.

Roth M, Tym E, Mountjoy CQ (1986) CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 149:698–709. https://doi.org/10.1192/bjp.149.6.698 CrossRefPubMed

57.

Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198. https://doi.org/10.1016/0022-3956(75)90026-6 CrossRefPubMed

58.

Lowry O, Rosebrough N, Farr A, Randall R (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275PubMed

59.

SPSS Incorporation (2006) Statistical Package for Social Science (SPSS). Release version 14 Chicago (IL). In: SPSS Inc. http://www.scielo.br/scielo.php?script=sci_nlinks&ref=000114&pid=S0365-0596201000010000300018&lng=pt. Accessed 12 Mar 2018

60.

Bermejo-Bescós P, Martín-Aragón S, Jiménez-Aliaga K et al (2013) Processing of the platelet amyloid precursor protein in the mild cognitive impairment (MCI). Neurochem Res 38:1415–1423. https://doi.org/10.1007/s11064-013-1039-7 CrossRefPubMed

61.

Vassar R (1999) Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286:735–741. https://doi.org/10.1126/science.286.5440.735 CrossRefPubMed

62.

Marcinkiewicz M, Seidah NG (2000) Coordinated expression of β-amyloid precursor protein and the putative β-secretase BACE and α-secretase ADAM10 in mouse and human brain. J Neurochem 75:2133–2143. https://doi.org/10.1046/j.1471-4159.2000.0752133.x CrossRefPubMed

63.

Yan R, Vassar R (2014) Targeting the β secretase BACE1 for Alzheimer’s disease therapy. Lancet Neurol 13:319–329. https://doi.org/10.1016/S1474-4422(13)70276-X CrossRefPubMedPubMedCentral

64.

Herrera-Rivero M, Soto-Cid A, Hernández ME, Aranda-Abreu GE (2013) Tau, APP, NCT and BACE1 in lymphocytes through cognitively normal ageing and neuropathology. An Acad Bras Cienc 85:1489–1496. https://doi.org/10.1590/0001-376520130013 CrossRefPubMed

65.

Herrera-Rivero M, Elena Hernández-Aguilar M, Emiliano Aranda-Abreu G (2015) A strategy focused on MAPT, APP, NCSTN and BACE1 to build blood classifiers for Alzheimer’s disease. J Theor Biol 376:32–38. https://doi.org/10.1016/j.jtbi.2015.03.039 CrossRefPubMed

66.

Holsinger RMD, McLean CA, Beyreuther K et al (2002) Increased expression of the amyloid precursor β-secretase in Alzheimer’s disease. Ann Neurol 51:783–786. https://doi.org/10.1002/ana.10208 CrossRefPubMed

67.

Yang L-B, Lindholm K, Yan R et al (2003) Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 9:3–4. https://doi.org/10.1038/nm0103-3 CrossRefPubMed

68.

Fukumoto H (2002) β-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 59:1381. https://doi.org/10.1001/archneur.59.9.1381 CrossRefPubMed

69.

Ahmed RR, Holler CJ, Webb RL et al (2010) BACE1 and BACE2 enzymatic activities in Alzheimer’s disease. J Neurochem 112:1045–1053. https://doi.org/10.1111/j.1471-4159.2009.06528.x CrossRefPubMed

70.

Holsinger RMD, Lee JS, Boyd A et al (2006) CSF BACE1 activity is increased in CJD and Alzheimer disease versus other dementias. Neurology 67:710–712. https://doi.org/10.1212/01.wnl.0000229925.52203.4c CrossRefPubMed

71.

Verheijen JH, Huisman LGM, Van Lent N et al (2006) Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. Clin Chem 52:1168–1174. https://doi.org/10.1373/clinchem.2006.066720 CrossRefPubMed

72.

Zhong Z, Ewers M, Teipel S et al (2007) Levels of β-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry 64:718. https://doi.org/10.1001/archpsyc.64.6.718 CrossRefPubMed

73.

Zetterberg H, Andreasson U, Hansson O et al (2008) Elevated Cerebrospinal Fluid BACE1 Activity in Incipient Alzheimer Disease. Arch Neurol 65:1102–1107. https://doi.org/10.1001/archneur.65.8.1102 CrossRefPubMed

74.

Mulder SD, van der Flier WM, Verheijen JH et al (2010) BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. J Alzheimer’s Dis 20:253–260. https://doi.org/10.3233/JAD-2010-1367 CrossRef

75.

Vassar R, Kandalepas PC (2011) The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer’s disease. Alzheimers Res Ther 3:20. https://doi.org/10.1186/alzrt82 CrossRefPubMedPubMedCentral

76.

Endres K, Deller T (2017) Regulation of alpha-secretase ADAM10 in vitro and in vivo: genetic, epigenetic, and protein-based mechanisms. Front Mol Neurosci 10:56. https://doi.org/10.3389/fnmol.2017.00056 CrossRefPubMedPubMedCentral

77.

Kögel D, Deller T, Behl C (2012) Roles of amyloid precursor protein family members in neuroprotection, stress signaling and aging. Exp Brain Res 217:471–479. https://doi.org/10.1007/s00221-011-2932-4 CrossRefPubMed

78.

Edwards DR, Handsley MM, Pennington CJ (2009) The ADAM metalloproteinases. Mol Aspects Med 29:258–289CrossRef

79.

Reiss K, Saftig P (2009) The A Disintegrin And Metalloprotease (ADAM) family of sheddases: physiological and cellular functions. Semin Cell Dev Biol 20:126–137. https://doi.org/10.1016/j.semcdb.2008.11.002 CrossRefPubMed

80.

Mathews PM, Cataldo AM, Kao BH et al (2000) Brain expression of presenilins in sporadic and early-onset, familial Alzheimer’s disease. Mol Med 6:878–891CrossRefPubMedPubMedCentral

81.

Borghi R, Piccini A, Barini E et al (2010) Upregulation of presenilin 1 in brains of sporadic, late-onset Alzheimer’s disease. J Alzheimer’s Dis 22:771–775. https://doi.org/10.3233/JAD-2010-100729 CrossRef

82.

Kakuda N, Shoji M, Arai H et al (2012) Altered γ-secretase activity in mild cognitive impairment and Alzheimer’s disease. EMBO Mol Med 4:344–352. https://doi.org/10.1002/emmm.201200214 CrossRefPubMedPubMedCentral

83.

Davidsson P, Bogdanovic N, Lannfelt L, Blennow K (2001) Reduced expression of amyloid precursor protein, presenilin-1 and rab3a in cortical brain regions in Alzheimer’s disease. Dement Geriatr Cogn Disord 12:243–250CrossRefPubMed

84.

Verdile G, Gnjec A, Miklossy J et al (2004) Protein markers for Alzheimer disease in the frontal cortex and cerebellum. Neurology 63:1385–1392. https://doi.org/10.1212/01.WNL.0000141848.45315.A6 CrossRefPubMed

85.

Capell A, Beher D, Prokop S et al (2004) γ-secretase complex assembly within the early secretory pathway*. https://doi.org/10.1074/jbc.M409106200 CrossRefPubMed

86.

Bustos V, Pulina MV, Bispo A et al (2017) Phosphorylated Presenilin 1 decreases β-amyloid by facilitating autophagosome–lysosome fusion. Proc Natl Acad Sci USA 114:7148–7153. https://doi.org/10.1073/pnas.1705240114 CrossRefPubMedPubMedCentral

87.

Pletscher A, Laubscher A (1980) Blood platelets as models for neurons: uses and limitations. J Neural Transm. https://doi.org/10.1007/978-3-7091-8582-7_2 CrossRef

88.

Freson K, Labarque V, Thys C et al (2007) What’s new in using platelet research? To unravel thrombopathies and other human disorders. Eur J Pediatr 166:1203–1210. https://doi.org/10.1007/s00431-007-0543-7 CrossRefPubMedPubMedCentral

89.

Catricala S, Torti M, Ricevuti G (2012) Alzheimer disease and platelets: how’s that relevant. Immun Ageing 9:20. https://doi.org/10.1186/1742-4933-9-20 CrossRefPubMedPubMedCentral

90.

Talib LL, Joaquim HP, Forlenza OV (2012) Platelet biomarkers in Alzheimer’s disease. World J psychiatry 2:95–101. https://doi.org/10.5498/wjp.v2.i6.95 CrossRefPubMedPubMedCentral

91.

Behari M, Shrivastava M (2013) Role of platelets in neurodegenerative diseases: a universal pathophysiology. Int J Neurosci 123:287–299. https://doi.org/10.3109/00207454.2012.751534 CrossRefPubMed

Titel: Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimer’s disease patients
verfasst von: Jessyka Maria de França Bram
Leda Leme Talib
Helena Passarelli Giroud Joaquim
Tamires Alves Sarno
Wagner Farid Gattaz
Orestes Vicente Forlenza
Publikationsdatum: 29.05.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 8/2019
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-018-0905-3

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2019

Antisaccade and prosaccade eye movements in individuals clinically at risk for psychosis: comparison with first-episode schizophrenia and prediction of conversion

Evaluation of the methoxy-X04 derivative BSC4090 for diagnosis of prodromal and early Alzheimer’s disease from bioptic olfactory mucosa

Relationship between duration of untreated prodromal symptoms and symptomatic and functional recovery

Neurobiology of the major psychoses: a translational perspective on brain structure and function—the FOR2107 consortium